Table 2.

Approved and investigational NK cell-based cancer immunotherapies.

S.No.	Therapy/Inhibitor/Antibody	Cancer type	Clinical Trial Stage	Clinical trial ID
1	Autologous NK cells	Advanced Kidney Cancer Metastatic melanoma Digestive cancer	Phase I/II	NCT02843607 NCT00631072 UMIN000007527
2	Allogenic NK cells	Metastatic Gastrointestinal Carcinoma High-risk AML (HINKL) Lymphoma and Solid tumors	Phase I/II	NCT02845999 NCT02229266 NCT01212341
3	NK Cell lines (Neukoplast™ (NK-92))	Hematological Malignancies	Phase I	NCT00990717 NCT00900809
4	CAR-NK cells	Relapsed/Refractory CD33+ AML Metastatic Solid Tumors Acute Lymphoblastic Leukemia	Pre-clinical/Phase 1/II	NCT02944162 NCT03415100 NCT01974479
5	IL-2	Lymphoma, lung cancer and melanoma	FDA approved
6	IL-15	Advanced Solid Tumors Acute Myelogenous Leukemia	Phase I	NCT01875601 NCT01572493 NCT01385423
7	IL-15 Superagonist (ALT-803)	Relapsed/Refractory AML	Phase II	NCT03050216
8	Anti-KIR mAB (IPH2101)	Smoldering Multiple Myeloma	Phase I	NCT01248455
9	Anti-NKG2A mAB (IPH2201/Monalizumab)	Metastatic squamous cell carcinoma Refractory Lymphoid Malignancies Hematological Malignancies Gynecological Malignancies	Phase I/II	NCT02643550 NCT02671435 NCT02921685 NCT02459301
10	mAB targeting tumor antigens (Rituximab/Trastuzumab/Cetuximab)	Non-Hodgkin’s Lymphoma Refractory Lymphoid Malignancies Breast and Gastric Cancer Advanced Solid Tumors Recurrent Non-small Cell Lung Cancer	FDA approved/Phase I/II	NCT03019640 NCT01181258 NCT02030561 NCT03319459 NCT02845856
11	Epigenetic drugs (Decitabine with Donor NK cells and Aldesleukin)	Relapsed/Refractory AML	Phase I	NCT02316964